The company expects that this development could improve the strength of its application to the FDA for new drug approval
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Investment is additive to KKR’s existing health care growth strategy
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company
Subscribe To Our Newsletter & Stay Updated
